等级
pharmaceutical primary standard
API类
piretanide
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
[S](=O)(=O)(N)c1c(c(cc(c1)C(=O)O)N3CCCC3)Oc2ccccc2
InChI
1S/C17H18N2O5S/c18-25(22,23)15-11-12(17(20)21)10-14(19-8-4-5-9-19)16(15)24-13-6-2-1-3-7-13/h1-3,6-7,10-11H,4-5,8-9H2,(H,20,21)(H2,18,22,23)
InChI key
UJEWTUDSLQGTOA-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Piretanide for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Effect of Na/K/2Cl transporter inhibition with piretanide on postischemic kidney function.
D Abendroth et al.
Transplantation proceedings, 28(1), 83-84 (1996-02-01)
R A Brown et al.
Journal of vascular research, 36(6), 492-501 (2000-01-12)
The inhibition by loop diuretics of K efflux (tracer (86)Rb) from the rat femoral arterial smooth muscle was measured in normotension and in DOCA-salt hypertension. The sensitivity sequence (bumetanide > piretanide > furosemide) was the characteristic pharmacological profile of (Na+K+Cl)
Bénédicte Buffin-Meyer et al.
Journal of the American Society of Nephrology : JASN, 15(4), 876-884 (2004-03-23)
In response to chronic treatment with furosemide, collecting ducts adapt their function to the initial loss of Na+ to prevent further Na+ loss and extracellular volume decrease. This adaptation, which includes the overexpression of Na+, K+-ATPase, is thought to account
[Study report: Hypertension therapy with organ protection. Piretanid and Ramipril: advantages with fixed combination].
Fortschritte der Medizin. Supplement : die Kongressinformation fur die Praxis, 164, 3-15 (1994-01-01)
L Thijs et al.
Journal of cardiovascular pharmacology, 26(1), 33-38 (1995-07-01)
In a double-blind, randomized, multicenter trial, we compared the efficacy and safety of the fixed combination of 5 mg ramipril and 6 mg piretanide and the respective component monotherapies in hypertensive patients [supine diastolic blood pressure (DBP) 100-114 mm Hg].
Active Filters
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门
